[HTML][HTML] Polypharmacy in Older Adults with Alzheimer's Disease
S Esumi, S Ushio, Y Zamami - Medicina, 2022 - mdpi.com
The number of patients with Alzheimer’s disease is increasing annually. Most of these patients
are older adults with comorbid physical illnesses, which means that they are often treated …
are older adults with comorbid physical illnesses, which means that they are often treated …
Association between immune-related adverse events and clinical efficacy in patients with melanoma treated with nivolumab: a multicenter retrospective study
…, K Takechi, Y Matsudate, R Utsunomiya, Y Zamami… - Clinical …, 2019 - Elsevier
… Kawazoe, Y. Matsudate, and R. Utsunomiya performed the survey of electronic records. …
Imanishi, Y. Zamami, and M. Chuma assisted with study design. All authors approved the final …
Imanishi, Y. Zamami, and M. Chuma assisted with study design. All authors approved the final …
Royal jelly ameliorates insulin resistance in fructose-drinking rats
Y Zamami, S Takatori, M Goda, T Koyama… - Biological and …, 2008 - jstage.jst.go.jp
MATERIALS AND METHODS Animals Six week-old male Wistar rats were used in this study.
They were given 15% fructose solution as drinking water ad libitum for 8 weeks. The control …
They were given 15% fructose solution as drinking water ad libitum for 8 weeks. The control …
Factors associated with immune checkpoint inhibitor–related myocarditis
Y Zamami, T Niimura, N Okada, T Koyama… - JAMA …, 2019 - jamanetwork.com
Results| We identified 1 979 157 reports including 13 096 cases that received 5 different ICIs.
Nivolumab was the most common ICI (n= 6029 of 13 096 [46.04%]). Reporting rates of …
Nivolumab was the most common ICI (n= 6029 of 13 096 [46.04%]). Reporting rates of …
[HTML][HTML] Drug-repositioning approaches based on medical and life science databases
Y Zamami, H Hamano, T Niimura, K Yagi… - Frontiers in …, 2021 - frontiersin.org
Drug repositioning is a drug discovery strategy in which an existing drug is utilized as a
therapeutic agent for a different disease. As information regarding the safety, pharmacokinetics, …
therapeutic agent for a different disease. As information regarding the safety, pharmacokinetics, …
New molecular mechanisms for cardiovascular disease: contribution of endothelium-derived hyperpolarizing factor in the regulation of vasoconstriction in peripheral …
X Jin, Y Satoh-Otonashi, Y Zamami, S Takatori… - Journal of …, 2011 - Elsevier
Endothelium regulates vascular tone via release of endothelium-derived relaxing factors (EDRF)
including nitric oxide (NO), prostaglandin I 2 (PGI 2 ), and endothelium-derived …
including nitric oxide (NO), prostaglandin I 2 (PGI 2 ), and endothelium-derived …
[HTML][HTML] Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study
…, M Goda, M Chuma, K Yagi, Y Zamami, Y Nishioka… - Scientific reports, 2020 - nature.com
Immune checkpoint inhibitors (ICIs) elicit antitumour effects by activating the host immunity
and cause immune-related adverse events (irAEs). ICI-related interstitial lung disease (ICI-ILD…
and cause immune-related adverse events (irAEs). ICI-related interstitial lung disease (ICI-ILD…
Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database
…, B Liaw, M Asada, T Niimura, Y Zamami… - Journal of neuro …, 2021 - Springer
Purpose To investigate the characteristics and risk factors for neurologic adverse events (AEs)
induced by immune checkpoint inhibitors (ICIs). Methods An observational, retrospective, …
induced by immune checkpoint inhibitors (ICIs). Methods An observational, retrospective, …
Quercetin diacylglycoside analogues showing dual inhibition of DNA gyrase and topoisomerase IV as novel antibacterial agents
AML Hossion, Y Zamami, RK Kandahary… - Journal of medicinal …, 2011 - ACS Publications
A structure-guided molecular design approach was used to optimize quercetin diacylglycoside
analogues that inhibit bacterial DNA gyrase and topoisomerase IV and show potent …
analogues that inhibit bacterial DNA gyrase and topoisomerase IV and show potent …
Trends in polypharmacy in Japan: a nationwide retrospective study
…, Y Zamami, H Hagiya, Y Tatebe… - Journal of the …, 2018 - Wiley Online Library
Objectives To describe and examine trends in polypharmacy according to age in Japan
from 2010 to 2016. Design Retrospective observational study. Setting Outpatient settings. …
from 2010 to 2016. Design Retrospective observational study. Setting Outpatient settings. …